Background
==========

Prostate cancer is the most common cancer in men resulting in over 232,090 new cases and 30,350 deaths annually \[[@B1]\]. For prostate cancer patients, metastatic disease reflects the most adverse clinical outcome. Osseous involvement with severe bone pain and spinal cord complications occur commonly in patients with metastatic disease \[[@B2]\]. However there is considerable heterogeneity in outcome after primary diagnosis and currently there are no morphologic or circulating biomarkers that can accurately predict the development of metastatic disease.

Metastatic prostate cancer represents the tumor\'s ability to escape from the primary organ and eventually colonize a distant site. Disruption of a complex set of biological processes must occur in order for tumor cells to leave the prostate and establish themselves in a different environment. Their altered interaction with the prostate microenvironment, including the stroma and extracellular matrix, their ability to migrate into the vasculature and establish themselves in secondary organs with recruitment of vascular supply represent disruption of normal cellular processes \[[@B3]\]. Understanding the molecular events involved in the development of metastatic prostate cancer has the potential to identify biological determinants that can aid in prognosis and development of more effective therapies.

Using gene expression microarrays, a number of studies have characterized expression profiles of prostate cancer, normal tissue and metastatic cancers. In some cases, correlations between tumor expression signatures, clinical parameters and outcome have been identified \[[@B4]-[@B11]\]. Unique profiles have been reported for untreated and short-term androgen ablation treated organ-confined disease and for metastatic disease, with a subset of genes differentiating metastatic androgen ablation resistant prostate cancer (AARPC) from androgen dependent metastatic cancers \[[@B10],[@B12]-[@B14]\]. In general, metastatic prostate cancer is characterized by changes in expression of genes involved in signal transduction, cell cycle, cell adhesion, migration and mitosis. In addition to these genes, AARPCs exhibit changes in expression of the androgen receptor and enzymes involved in the sterol biosynthesis pathway \[[@B12]\].

Some of the genes previously reported as highly downregulated in prostate tumors may reflect the differences in cellular content of metastatic and organ-confined tissues rather than intrinsic differences in biology. In contrast with organ-confined prostate tumors which are composed of a mixture of glandular epithelial, smooth muscle and other stromal cells, metastatic tissue samples are almost exclusively epithelial, with minimal supporting stroma and absence of smooth muscle. In this study, we characterize gene expression in androgen ablation resistant metastatic tumors after removing potentially uninformative stromal genes. The deleted stromal genes consist of those reported in a recent report characterizing the gene expression patterns in the prostate stroma, tumor and normal epithelium \[[@B15]\]. Our results provide novel insights into the biology of metastasis.

Methods
=======

Tumor sample procurement
------------------------

All tissue samples were acquired from the Health Sciences Tissue Bank of the University of Pittsburgh Medical Center under stringent Institutional Review Board guidelines with appropriate informed consent. The 18 donor and 64 primary prostate tumor samples have been described previously \[[@B7]\]. Specimens were received directly from the operating room. Samples (\>500 mg) were excised and snap frozen in liquid nitrogen within 30 min of excision and stored at -80°C until extraction of RNA. Metastatic tumor samples were obtained from a warm autopsy program and processed similarly to primary tumors. An H&E stained frozen section of each sample was evaluated by a pathologist, to determine epithelial and stromal content and verify the presence of tumor in the sample. Dissection of the frozen tissue block was performed with the guidance of a marked H & E slide to minimize the presence of host tissue in the metastatic samples. All samples used in the study contained \>80% tumor. Metastatic tumor samples were minced and divided into two equal portions to be extracted with the sample protocol used for each set of primary tumors.

Clinical profile of cases
-------------------------

The clinical characteristics of the 64 primary tumor samples used in the Affymetrix portion of our study have been previously described \[[@B6],[@B7]\]. These cases have a mean follow-up time of 3 years. The metastatic samples consisted of 24 tissues derived from 4 patients (Table [1](#T1){ref-type="table"}). All patients with metastatic disease had received androgen ablation therapy and had shown progression of disease while on androgen ablation. The clinical characteristics for the additional 10 primary prostate tumor cases used in the CodeLink study are shown in Table [1](#T1){ref-type="table"}.

RNA extraction
--------------

RNA purification for the 64 primary samples has been previously described \[[@B6]\]. The set of metastatic samples analyzed with the Affymetrix platform was extracted with the same methodology. The set of metastatic samples and primary tumors analyzed with the CodeLink platform were extracted using the RNeasy kit (Qiagen, San Diego, CA). For the metastatic samples, one sample did not have enough for extraction with the Qiagen method, only 23 metastatic samples are included in the CodeLink assays. The concentration of each total RNA sample was measured with a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies,Wilmington, DE). RNA integrity was determined by capillary electrophoresis using an Agilent 2100 Bioanalyzer (Agilent, Willmington, DE).

cRNA preparation and gene expression assays
-------------------------------------------

cRNA was prepared and hybridized to Affymetrix GeneChip HGU95av2, HGU95b and HGU95c arrays (Affymetrix, Santa Clara, CA) as previously described \[[@B6]\]. For gene expression profiling with the CodeLink Gene Expression System (GE Healthcare, Piscataway, NJ), biotin-labeled cRNA was prepared as previously described \[[@B16]\]. Ten micrograms of biotin-labeled cRNA product from each sample were then fragmented with RNA fragmentation buffer at 94°C for 20 minutes. Hybridization mix was prepared according to the manufacturer\'s instructions and the final volume was adjusted to 260ul using nuclease-free water. The hybridization mix was heat denatured at 90°C for 5 minutes, cooled on ice and then applied to Human Uniset 20 K arrays (GE Healthcare, Piscataway, NJ). Arrays were incubated at 37°C for 18 h with shaking at 60 rpm in an Innova hybridization oven (New Brunswick, Edison, PA).

After hybridization, arrays were placed in a pre-heated (46°C) chamber filled with 0.75 × TNT (0.75 M Tris-HCL, *p*H 7.6, 3.75 M NaCl, Tween-20, and milli-Q water) and incubated at 46°C for 1 hour. Arrays were then stained with Streptavidin-Alexa Fluor 647 (Molecular Probes, Grand Island, NY) for 30 minutes at room temperature. Upon the completion of staining, the arrays were washed three sequential times in fresh 1 × TNT (1 M Tris-HCL, *p*H 7.6, 5 M NaCl, Tween-20, and milli-Q water) and then washed two final times in fresh solutions of 0.05% Tween-20 and 0.1 × SSC with gentle agitation. All arrays were dried by centrifugation at 2000 rpm for 3 minutes.

Affymetrix arrays were scanned in an Affymetrix GCS3000 Scanner (Affymetrix, Santa Clara, CA). CodeLink arrays were scanned with the GenePix 4000B scanner using GenePix Pro 4.1 software (Molecular Devices, Sunnyvale, CA).

Gene expression data analysis
-----------------------------

The raw scanned array images from the Affymetrix GeneChip U95 arrays were processed using GCOS 1.1 software using the MAS5 algorithm (Affymetrix Corporation, Santa Clara, Ca) to generate probe cel intensity (\*.cel) files. Data normalization to remove variation in overall chip intensities was performed by global scaling to a chip mean target intensity of 200 (MAS 5.0). Data for U95Av2, B and C arrays were combined for further analyses.

To identify differentially regulated genes in both datasets, these were analyzed with the Significance Analysis of Microarrays software (SAM v 1.2) \[[@B17]\]. Prior to analysis, genes that showed low variation across all samples were removed by using the filtering option in the Avadis 3.3 Pride Software (Strand Life Sciences, Bangalore, India) data analysis tool. To avoid false results due to difference in the tissue composition of metastatic and primary tumors, genes identified as being highly expressed in the prostatic stroma as per Stuart *et al*\[[@B15]\] were also removed. In all 1506 stromal genes and 7678 invariant genes were removed from the Affymetrix dataset. SAM generated gene lists with the lowest false discovery rates (FDR) were further analyzed for gene ontology (GO) and pathway annotations using NIH\'s DAVID annotation tool \[[@B18]\].

For CodeLink arrays, image files were analyzed with the CodeLink Expression Analysis Software version 4.1 (GE HealthCare) with use of the normalized intensity values in downstream analysis. For cross-platform comparison, Affymetrix probe sets and Codelink identifiers were mapped to Unigene ids using the DAVID annotation tool (see above). Expression data from both platforms was compared using z-transformation. Hierarchical clustering was performed using Eisen\'s Cluster and Treeview \[[@B19]\]. Data from Affymetrix experiments has been submitted to NCBI\'s Gene Expression Omnibus (GEO) as series GSE6919, with the following accession numbers GSE6604 (normal donor prostate), GSE6605 (metastatic prostate tumors), GSE6606 (primary prostate tumors) and GSE6608 (normal prostate tissue adjacent to tumor). Data from the CodeLink platform have been submitted to GEO with the accession number GSE6752 (primary and metastatic prostate tumors).

Quantitative real-time PCR
--------------------------

Differential expression of ten genes in primary and metastatic prostate cancer samples was verified with quantitative real-time PCR (QPCR) with the ABI PRISM^®^7000 sequence detection system (Applied Biosystems, Foster City, CA). Three selected RNA samples from each patient were pooled together (except for patient FB666 n = 1) and therefore four RNA samples, each representing one patient, were tested. RNA samples were first heat-denatured at 70°C for 10 minutes in an Eppendorf master cycler (Eppendorf, Westbury, NY) and then chilled immediately on ice. cDNAs were reversely transcribed from one microgram of RNA using the M-MLV Reverse Transcriptase kit (Invitrogen, Carlsbad, CA), as recommended by the manufacturer. QPCR was performed based on the manufacturer\'s instructions with TaqMan Gene Expression Assays (Applied Biosystems) for the following genes: EGR3, SYNPO2, ANGPT2, SPP1, FOXM1, ADM, RDX, TGFBRAP1, MAK and EGR1(assay IDs: Hs00231780_m1, Hs00326493_m1, Hs01048047_mH, Hs00959010_m1, Hs00153543_m1, Hs00969450_g1, Hs00988414_g1; Hs01093285_m1; Hs01048300_m1, Hs00152928_m1). When multiple TaqMan assays for one gene were available, the assay that interrogated the sequence closest to the target sequence in the Affymetrix arrays was chosen. PCR cycles were performed according to the assay instructions in an ABI PRISM^®^7000 Sequence Detection System (Applied Biosystems). Relative quantification of the expression level of each transcript in each sample was calculated using the Delta-Delta CT method in the ABI PRISM 7000 Sequence Detection System Software (Applied Biosystems) \[[@B20]\]. Human reference RNA from Stratagene (Stratagene Corp., La Jolla, CA) was used as the calibrator (untreated control) and human glucuronidase beta (GUSB) gene was used as the endogenous reference gene (Forward primer: GGA ATT TTG CCG ATT TCA TGA; Reverse primer: CCG AGT GAA GAT CCC CTT TTT; Probe: 6FAM-AAC AGT CAC CGA CGA GAG TGC TGG G-TAMRA).

Results
=======

Differential gene expression in metastatic prostate cancer and the role of stromal content in defining true downregulated genes
-------------------------------------------------------------------------------------------------------------------------------

Differential expression analysis of the metastatic and primary tumor samples shows that a large number of the most highly downregulated genes such as *TAGLN*, *ACTG2*, *TPM1*, *MYH111*and *DES*have been previously identified as expressed mostly in the prostatic stromal cells \[[@B15]\]. Since only the epithelial component of prostate cancer is present in metastatic tumors, this result most likely reflects the lack of stroma in metastases, and not a true down-regulation of these genes in the metastatic epithelial cells. Therefore, based on a recent report characterizing cell type specific gene expression in the prostate \[[@B15]\], we removed the set of genes expressed mainly by the stromal cells of the primary tumors. In all 1506 transcripts associated with a stromal signature were deleted prior to further analysis. Since the stromal genes were characterized using the U95Av2 chip and our analysis includes u95Av2, B and C chips, only stromal genes represented by probe sets on U95Av2 were removed in this modified analysis. SAM analysis shows that 1277 genes are up and 977 genes are downregulated at least 2 fold at the lowest FDR (0.01), in metastatic prostate samples (see Additional file [1](#S1){ref-type="supplementary-material"}). A list of the top 50 up and top 50 down regulated genes at the lowest fdr, after removing ESTs and uncharacterized clones is shown in Table [2](#T2){ref-type="table"}. This list includes signal transducers, cell cycle regulators, metabolic enzymes and cell adhesion molecules. Some of the most upregulated genes in our list are *EIF1AX*, *AR*, *HSPD*1 and *HSPCA*, *K-ALPHA1*, *MLL5*, *UGT2B15*, and some of the most downregulated genes include *WNT5B5, ANXA11, FOS*and *SFRP1*.

Metastatic samples are heterogenous in gene expression
------------------------------------------------------

Using immunohistochemistry (IHC) Shah *et al*. have shown that metastatic samples are highly heterogenous in expression of prostate specific markers leading to the hypothesis that at the molecular level, metastatic prostate cancer may represent multiple diseases even within the same patient \[[@B21]\]. We examined the expression of several transcripts markers including some studied by Shah *et al*. and confirmed the heterogeneity of expression levels in metastatic prostate cancer tissues. Expression values in donor samples, primary and metastatic samples were compared. Prostate specific antigen (*PSA*/*KLK3*) remains high in some metastatic samples and is low or absent in others, even within the same patient (Figure [1](#F1){ref-type="fig"}). Interestingly, *AMACR*, another biomarker for prostate cancer \[[@B22]\] expresses a heterogenous expression pattern similar to *PSA*. *HPN*, which is overexpressed in primary cancer maintains high expression in the metastatic samples in our study. *AR*, while overexpressed in 23 out of the 24 metastatic samples, shows highly variable expression values in individual samples. The proto-oncogenes *FOS*and *JUNB*, which are both overexpressed in primary tumors, are consistently downregulated in all metastatic samples.

Genes regulated in all metastatic cases
---------------------------------------

Hierarchical clustering analysis reveals that gene expression in metastatic samples is more variable between patients than between different metastatic sites from each patient (Figure [2](#F2){ref-type="fig"}). Although the 24 metastatic samples represent tissues from 6 metastatic sites (Table [1](#T1){ref-type="table"}), no organ specific clusters were detected (Figure [2](#F2){ref-type="fig"}) whereas samples from the same patient tend to cluster together. Statistical comparison of organ-specific expression profiles was not attempted due to unequal distribution of samples from different metastatic sites.

In order to identify probe sets that are similarly regulated in every patient, and therefore likely to represent a specific metastatic profile, the SAM differentially expressed gene list at a FDR of 2% was further filtered. For each gene on this list, a patient specific median expression value was calculated from the multiple samples from each patient. Patient P4 had only sample and this sample\'s signal value was considered the median value. The median values were then compared to the median value of the primary samples and those probe sets whose median value showed equal or more than a 2 fold change in every patient were considered part of the metastatic prostate cancer signature. Under this criteria 415 transcripts are upregulated and 364 are downregulated in all patients with metastasis (see Additional file [2](#S2){ref-type="supplementary-material"}). A truncated gene list consisting of genes regulated at least 3 fold in all patients is shown in Table [3](#T3){ref-type="table"}. Upregulation of *AR*in all samples from metastatic cancer patients represents a known \"androgen resistant\" or AARPC (androgen ablation resistant prostate cancer) phenotype \[[@B12]\]. The transcripts identified as differentially expressed in our study exhibit similarities with a previous study of AARPC tumors \[[@B10],[@B12]\]. Cytokeratins 5 and 15 (*KRT5*/*KRT15*), markers of basal cells in prostate glands, show uniform downregulation in all metastatic tumors, confirming the absence of basal epithelial cells.

Biological annotation of differentially expressed genes in metastatic prostate cancer
-------------------------------------------------------------------------------------

The list of differentially expressed transcripts at least 2 fold in all patients was further analyzed for biological themes and gene ontology (GO) using the NIH\'s DAVID annotation tool. This analysis revealed that metastatic prostate cancer exhibits altered regulation of amino acid, carbohydrate and nucleotide metabolism consistent with the proliferative capacity and altered energy needs of metastatic tumors (data not shown). In the context of prostate cancer biology, genes involved in cell-adhesion, bone remodeling, cell-cycle and transcription are of particular interest (Table [4](#T4){ref-type="table"}). Disruption of cell adhesion and altered interaction with the extracellular matrix is a hallmark of metastatic tumors \[[@B3]\]. In agreement with this, the secreted phosphoprotein and cell adhesion molecule osteopontin (SPP1) is one of the most highly upregulated transcripts in our metastatic samples. Elevated expression of SPP1 has been correlated with poor prognosis in prostate tumors and other cancers and it has often been implicated in metastasis to bone and other organs \[[@B2],[@B23]-[@B28]\]. In all 29 probe sets representing cell adhesion genes are altered in all metastatic samples. This gene list includes *FN1*, *ITGB8*, *THBS*2, *HNT*and *CDH10*. Genes involved in bone remodeling such as *BMP4*and *ANKH*are also altered in expression, although none of the samples in our study are bone metastatic samples suggesting that these proteins may also be involved in cancer metastasis to other organs.

Disruption of the cell cycle is highlighted by the presence of a large number of cell-cycle related transcripts in the list of differentially expresed genes in all metastatic samples. The list contains 37 cell cycle genes, and includes *SEP4*, *SEP7*, *PTN*and *VEGF*. Similarly, a large number of transcription factors (67) including *AR*, *SRY*, *FOS*and *EGR3*, are differentially expressed. Two members of the winged-helix family of transcription factors, *FoxP1*and *FoxM1*, show upregulation in the metastatic samples. Interestingly, *FoxM1b*has been shown to promote progression of prostate carcinomas in an experimental model \[[@B29]\].

The MAP kinase signaling pathway was also identified as being important in the metastatic process, with 26 probe sets involved in this pathway being differentially expressed in all metastatic samples. The regulated genes include *DUSP1*, *DUSP2*, *DUSP8*, *MAP3K8*, *MAP4K4*, *FGF13*, *FGFR2*and *FOS*. Involvement of MAP kinase in androgen receptor signaling has been previously described \[[@B30]\].

Validation of differentially expressed transcripts with an independent set of primary tumors and different gene expression platforms confirms gene expression profiles of metastatic prostate cancer
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gene expression analysis with the CodeLink Uniset 20 K microarray was carried out for 23 of the metastatic samples and compared to an independent set of 10 primary tumors. Similar to the Affymetrix analysis (see above), hierarchical clustering of the CodeLink data set reveals heterogeneity in expression and no organ-specific clustering (data not shown). Comparison of results with the Affymetrix based dataset, based on genes with common Unigene ids on both platforms, show a similar pattern of differentially expressed genes. Of the top 1000 up and down regulated transcripts from each platform, approximately 70% share common unigene ids and of these 22% of the genes are identified as regulated by both platforms (see Additional file [3](#S3){ref-type="supplementary-material"}). This level of correlation is significant, given the well-documented difficulties in cross-platform comparisons of expression data \[[@B31],[@B32]\]. Examples of z-transformed expression values for selected genes in both platforms are shown in Figure [3](#F3){ref-type="fig"}.

Additionally, real-time quantitative PCR (QPCR) assays were performed for a selected set of genes in pooled samples for each patient with metastatic disease and 5 of the primary tumors from the CodeLink set. The transcripts for this analysis were chosen to represent diverse biological processes and were chosen from the differentially expressed genes identified as up/down-regulated in the Affymetrix/Codelink data comparison. As shown in Figure [4](#F4){ref-type="fig"}, qPCR assays confirmed the results from the microarray platforms. *SYNPO2*and *EGR3*, which are downregulated and *RDX*and *FOXM1*, which are upregulated in the microarray analysis exhibit a very similar expression pattern in the qPCR analysis. Interestingly, *FoxM1*is consistently upregulated in metastases, while RDX was upregulated in only two of the four patients with metastatic disease, confirming the heterogeneity of metastatic prostate cancer.

Discussion
==========

Despite extensive research, the molecular mechanisms of metastatic prostate cancer and androgen resistance development are still poorly understood. Our study shows that a number of biological processes including cell adhesion, cell cycle and transcription regulation are altered in metastatic disease when compared to primary tumors, and point to specific transcripts that participate in the metastatic process.

Previous investigators have reported differences in gene expression profiles of metastatic and primary prostate cancer \[[@B10],[@B12],[@B14],[@B21]\]. Our results show partial overlap with these previous characterizations of metastatic disease. Some genes that are in concordance with these studies include transcription factors such as *FOXM1*, and c-*FOS.1*. Differences in patient demographics, pathology and treatment, non-standard tissue handling, experimental and statistical methods may all contribute to differences in gene lists. Differences with other published gene lists might also reflect the fact that in our study, only samples from patients with androgen-insensitive prostate cancer were used. Additionally, in our experimental design we have incorporated features that increase the significance of our findings and increase the likelihood that the genes identified truly reflect the biology of metastatic prostate cancer. First, by subtracting transcripts previously identified as being expressed by the prostatic stroma, we have incorporated previous knowledge about the expression profiles of different components of prostate tumors in order to focus on those transcripts intrinsic to metastatic cells. This takes into account the fact that metastatic tumors do not contain all the tissue elements present in organ-confined tumors. The major benefit of this strategy is to better define the genes that are down-regulated in metastatic tumor cells. Second, by analyzing multiple tumor samples from each patient, we have addressed the fact that metastatic prostate cancer shows significant heterogeneity, even within the same patient \[[@B21]\]. This is corroborated by our results. and we address this issue by focusing our analysis on the transcripts that show significant differential expression in all metastatic sites within and between patients.

Multiple biological processes appear to be altered in metastatic prostate cancer. One common theme that has emerged from studies of metastatic disease is the central role of the androgen receptor in the development of androgen resistant disease. Several mechanisms including amplification of the *AR*gene, upregulation of mRNA expression to allow binding by low levels of androgens, mutations in the ligand binding domain (LBD) that allow the receptor to be activated by antagonists, and alteration in the normal *AR*signaling pathway, have been proposed to explain the ability of prostate cancer to recur in the presence of androgen ablation therapy \[[@B33],[@B34]\]. Consistent with previous observations, *AR*is up-regulated in all metastatic samples in our study. Similarly, gene expression changes of the MAP kinase pathway in metastasis may be related to the development of the AARPC phenotype. The gene list from our analysis shares some similarities with mouse xenograft prostate cancers models (CWR22) of androgen independence. *MSMB*, *CCND1*, *EFNA3*, *FKBP*and *ADM*, *HGF*are similarly regulated in mouse models and in our study \[[@B35]-[@B37]\].

Changes in the expression level of several additional transcripts may reveal clues about the mechanism of metastasis and androgen resistance. We find upregulation of the enzyme *UGT2B15*in all metastatic patients. Upregulation of *UGT2B15*in androgen independent prostate cancer has been reported previously \[[@B14]\]. This increase appears paradoxical, since *UGT2B15*is involved in hormone inactivation. However, as suggested by Stanbrough *et al*\[[@B14]\], upregulation of multiple genes related with androgen metabolism might reflect that metastatic tumor cells have an increased capacity to convert weak androgens into testosterone or DHT. However, in contrast to their findings, transcripts for *AKR1C3*, *SRD5A1*, *HSD3B2*, *AKR1C2*, *AKR1C1*are not consistently upregulated in the metastatic samples in our study. Interestingly, when reviewing individual values for each sample, some metastases indeed show higher levels for some of these transcripts, which might reflect the heterogeneity of metastatic prostate cancer phenotypes. Another possible explanation for this discrepancy is that the metastatic samples used by Stanbrough *et al*. are all from bone metastases and this type of sample is not represented in our study. Clearly, further investigation into the role of these pathway genes in the development of androgen resistance by metastatic samples is needed.

Several genes involved in cell-cell interaction and cell adhesion appear to be up-regulated in these tumors. *SPP1*(osteopontin), a secreted, integrin-binding glycoprotein with adhesive properties, has been shown to be correlated with metastasis to the bone and with poor prognosis in various cancers and is highly upregulated in all the metastatic samples in our study. Elevated plasma osteopontin levels have also been correlated with lower survival and bone metastasis in hormone resistant prostate cancer \[[@B25]\]. Interestingly, Stanborough and collaborators also identified *SPP1*as upregulated in their metastatic samples, however, their interpretation was that this increase was part of the bone response to the metastases. Our study confirms that upregulation of *SPP1*is a feature intrinsic to androgen-resistant metastatic prostate cancer, independent of the site of metastasis. It has been postulated that metastasis to specific target organs may require not only expression of *SPP1*but an additional set of signaling molecules that promote metastasis to the specific organ. *SPP1*when expressed with *IL11*has been shown to promote metastasis of breast cancer cells to the bone \[[@B38]\] but not to the adrenal medulla. Further detailed studies are required to address the specific role of *SPP1*and other co-expressed genes in prostate cancer metastasis and whether *SPP1*represents a potential therapeutic target for androgen-resistant disease. Interestingly, the gene expression profile termed as \"bone module\" and postulated as a hallmark of tumor metastasis to bone \[[@B39]\] is not dysregulated in our study, most likely reflecting the fact that we did not assay bone metastatic samples. It is also possible, that the role that *SPP1*plays in metastasis to bone and/or other organs may involve distinct mechanisms \[[@B38]\].

Metastatic tumors have been described as undergoing an epithelial to mesenchymal transition with loss of the differentiated phenotype. Downregulation of transcription factors such as *JUN*has been observed in advanced stages of other cancers and its loss of activity has been postulated to be involved in this transition \[[@B40]\]. In our study, both *FOS*and *JUNB*, which are upregulated in primary tumors compared to normal prostate tissue are highly downregulated in the metastatic samples. *FBN*, also representative of the EMT transition \[[@B38]\] is overexpressed in our metastatic samples. Our analysis has also identified a number of additional genes, such as *KLK11*,*STC1*and *S100A8*that are uniformly regulated in all metastatic patients. The role of *S100A8*in prostate cancer has been studied with evidence suggesting that it is elevated in prostate cancer and may be involved in MAP kinase and *NFK-B*signalling \[[@B41],[@B42]\]. *STC1*, involved in calcium homeostasis, has been reported to have osteoblastic and angiogenic modulator properties with altered expression in some cancers \[[@B43]-[@B45]\]. The serine protease *KLK11*appears to be regulated in prostate cancer with negative correlation between aggressiveness and expression \[[@B46]\].

A recent study observed overexpression of 62 genes due to surgical manipulation related ischemia of the prostate \[[@B47]\]. In our study, 12 out of the 62-gene ischemia profile are downregulated in all metastatic samples. This gene list includes *DUSP1*, *BTG2*, *IER2*, *PTGS2*, *NR4A1*, *AMD1*, *C20orf35*, *KLF4*, *RAB4A*, *KLF6*, *CTGF*and *GOLPH2*. In our data set, these genes represent only 0.01% of the total number of genes differentially regulated in all metastatic samples. Since our metastatic samples all originate from autopsy studies, it is likely that they had been exposed to longer ischemia than the organ confined samples obtained from surgical specimens. Thus, if the differences we observed were related to the ischemia, we would have expected an increase in the expression of these genes, and not the observed downregulation. Therefore, it is unlikely that surgical manipulation can explain the differential gene expression between metastatic and primary tumors.

Conclusion
==========

In summary, our results support the roles for specific cell adhesion, androgen metabolism and transcription factor genes in the development of androgen-independent metastatic prostate cancer. Furthermore, the differentially expressed transcripts in metastatic tumors that we report have been validated with two independent sets of primary tumors, two gene expression microarray platforms, and selected genes were further validated by qRT-PCR. Our results corroborate the notion that metastatic prostate cancer is quite heterogeneous within a single patient. Despite this heterogeneity our experimental design allowed us to identify common expression profiles for androgen-independent metastatic prostate cancer.
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![Box plots of gene expression values for selected genes in donor prostate samples, primary prostate cancer and metastatic prostate samples.](1471-2407-7-64-1){#F1}

![**Hierarchical clustering of primary and metastatic prostate cancer samples**. The 24 metastatic (Mets P1, Mets P2, Mets P3 and Mets P4) and 64 primary tumor samples were clustered. The top row of color coded boxes represents metastatic or primary samples; the bottom row represents the organ from which the sample was obtained.](1471-2407-7-64-2){#F2}

![**Comparison of Z-transformed expression values between the Affymetrix and Codelink platforms**. Gene expression data from Affymetrix and CodeLink experiments was Z-transformed to allow comparison. Data for selected differentially expression genes is shown.](1471-2407-7-64-3){#F3}

![**Validation of differentially expressed genes with quantitative real time PCR**. QPCR was performed on RNA from samples used in the CodeLink analysis. Three selected metastatic RNA samples from each patient were pooled together (except for patient FB666 n = 1) and therefore four RNA samples, each representing one metastatic patient and 5 primary tumors were tested. The insert shows average expression values for metastatic and primary tumors.](1471-2407-7-64-4){#F4}

###### 

Clinical variables for primary and metastatic prostate cancer samples used in this study

  **Prostate Cancer Tissue Samples**   **No. of Samples**   **Number of Patients**   **Microarray Platform**   **Clinical Information**     
  ------------------------------------ -------------------- ------------------------ ------------------------- ---------------------------- --------------------
                                       64                   64                       Affymetrix                Please see reference \[7\]   
                                                                                                                                            
                                                                                                               **Gleason Score**            **No. of Cases**
                                                                                                                                            
                                                                                                               7                            10
                                                                                                                                            
  Primary Tumors                       10                   10                       CodeLink                  **Pathological Stage**       **No. of Cases**
                                                                                                                                            
                                                                                                               2B                           6
                                                                                                               3A                           3
                                                                                                               3B                           1
                                                                                                                                            
                                                                                                               **Patient ID**               **No. of Samples**
                                                                                                                                            
                                                                                                               FB6561                       11
                                                                                                               FB666                        1
                                                                                                               FB667                        8
                                                                                                               FB669                        5
                                                                                                                                            
                                                                                                               **Metastatic Sites**         **No. of Samples**
                                                                                                                                            
  Metastatic                           24                   4                        Affymetrix                Liver                        5
                                                                                                               Para Aortic Lymph Node       3
                                                                                                               Para Tracheal Lymph Node     8
                                                                                                               Retroperitoneal Lymph Node   3
                                                                                                               Lung                         1
                                                                                                               Adrenal                      2

###### 

Top 100 genes differentially expressed in metastatic samples compared to primary tumor samples

  **Gene Symbol**   **Probe_ID**   **d_Value**   **Fold Change**
  ----------------- -------------- ------------- -----------------
  EIF1A             34278_at       19.46         3.56
  AR                1577_at        16.04         10.09
  AK3               48822_s\_at    15.18         3.03
  EIF1A             663_at         14.17         2.69
  PABPC1            44806_at       14.17         3.57
  \-\--             45092_at       13.16         3.66
  HSPD1             37720_at       12.80         2.80
  \-\--             54219_at       12.78         3.23
  LCHN              58324_at       12.39         3.49
  MLL5              58271_at       12.15         2.45
  \-\--             59350_at       11.98         3.22
  \-\--             49558_at       11.93         2.73
  LARP              41829_at       11.60         3.14
  IBTK              52482_at       11.41         3.30
  GIT1              43805_f\_at    11.41         2.49
  \-\--             56056_at       11.31         2.64
  FLJ20736          64662_at       11.21         4.32
  AR                1578_g\_at     11.20         6.19
  RALA              39253_s\_at    11.19         3.61
  HN1               56429_g\_at    11.17         2.89
  \-\--             54236_at       11.04         3.82
  HSPCA             32316_s\_at    10.94         2.68
  NUCKS             59778_f\_at    10.93         2.44
  SOD1              36620_at       10.87         2.16
  K-ALPHA-1         32272_at       10.72         2.23
  \-\--             46558_at       10.70         4.70
  \-\--             33207_at       10.62         2.25
  VPS28             43061_i\_at    10.61         2.19
  BASP1             32607_at       10.57         4.15
  CBX4              51842_at       10.49         3.06
  \-\--             43680_at       10.45         4.85
  GRB2              33855_at       10.44         2.55
  \-\--             63147_at       10.43         3.86
  UGT2B15           63915_f\_at    10.35         3.07
  METTL2            48730_s\_at    10.26         2.24
  \-\--             59101_at       10.11         7.12
  MLL5              58690_at       10.02         2.24
  G3BP              41133_at       10.00         2.25
  AK3               32331_at       9.96          2.31
  H2AV              39092_at       9.92          3.25
  SDCCAG3           43014_at       9.91          6.04
  FLJ10613          59989_s\_at    9.82          2.20
  YY1               891_at         9.70          2.08
  \-\--             49326_at       9.59          2.20
  \-\--             42646_at       9.50          5.45
  LOC90462          54342_at       9.44          4.55
  \-\--             55393_at       9.42          3.51
  DDX17             41260_at       9.35          4.97
  \-\--             63115_at       9.34          3.07
  \-\--             57160_at       9.34          2.11
  ETR101            36097_at       -6.98         -3.85
  MAGED2            34859_at       -7.00         -2.22
  \-\--             50411_at       -7.00         -3.57
  MGC4342           48094_at       -7.01         -2.22
  HT023             43461_g\_at    -7.01         -2.78
  SFRP1             32521_at       -7.02         -6.25
  CRYL1             56407_at       -7.04         -2.04
  REA               37364_at       -7.05         -2.17
  ARL5              59499_at       -7.08         -2.50
  NY-REN-45         57833_s\_at    -7.09         -2.08
  POMT1             46723_at       -7.12         -3.23
  MRC2              63996_at       -7.13         -2.38
  B3GALT3           53879_at       -7.16         -3.13
  NR4A1             280_g\_at      -7.21         -7.14
  MUM2              65822_at       -7.23         -2.38
  LOC113246         46712_at       -7.31         -2.17
  GLTSCR2           61109_at       -7.33         -2.44
  FLJ20542          50164_at       -7.36         -3.13
  APCDD1            56272_at       -7.42         -2.70
  AIM1              32112_s\_at    -7.45         -3.70
  FOS               1916_s\_at     -7.51         -7.69
  FOS               1915_s\_at     -7.56         -9.09
  PILB              43370_at       -7.56         -2.08
  C20orf178         45298_at       -7.59         -2.13
  B3GAT1            65859_at       -7.60         -2.13
  FLJ10283          46261_at       -7.68         -2.27
  RAB34             45269_at       -7.71         -10.00
  FLJ20069          61701_at       -7.71         -3.23
  PYGB              59669_at       -7.77         -2.70
  RPS27L            56410_at       -7.80         -2.27
  TOMM20            36198_at       -7.91         -2.13
  \-\--             43819_g\_at    -7.91         -3.13
  STAT6             41222_at       -7.92         -2.78
  SELM              64449_at       -7.95         -9.09
  BOC               52999_at       -8.15         -4.17
  \-\--             44746_at       -8.20         -2.13
  SMBP              46307_at       -8.28         -3.23
  WNT5B             61330_at       -8.34         -3.33
  FLJ22386          50198_at       -8.43         -4.55
  WNT5B             58787_at       -8.61         -2.27
  ZDHHC4            45807_at       -8.81         -2.13
  YF13H12           36170_at       -8.84         -2.08
  HPIP              38063_at       -9.04         -2.33
  ANXA11            55664_at       -9.16         -2.94
  WNT5B             66142_s\_at    -9.33         -4.17
  WAS               38963_i\_at    -9.43         -2.50
  JFC1              44820_f\_at    -9.45         -3.33
  JFC1              48805_f\_at    -9.48         -2.44
  WNT5B             61292_s\_at    -9.86         -7.14
  CIRBP             39864_at       -10.94        -3.70

Gene expression data from the Affymetrix platform for 25 metastatic and 64 primary tumor samples was analyzed for differential gene expression by SAM. The differentially expressed genes with the lowest FDR were sorted by fold change. The top 100 genes, organized by fold change are shown.

###### 

Transcripts with median values with at least 3 fold difference between metastatic and primary tumor samples

  **Gene Symbol**                 **Probe_ID**   **P1**    **P2**    **P3**   **P4**
  ------------------------------- -------------- --------- --------- -------- --------
  **Upregulated Transcripts**                                                 
  HBB                             32052_at       22.37     5.78      13.25    56.28
  SPP1                            34342_s\_at    24.16     26.78     4.75     5.39
  HBA1///HBA2                     31525_s\_at    15.14     4.47      13.65    108.11
  LGR4                            43585_at       7.39      7.43      20.89    24.82
  AR                              1577_at        14.35     12.97     12.24    14.78
  PRO1073                         49666_s\_at    4.56      13.25     10.01    13.5
  UTRN                            42646_at       10.11     6.02      12.11    16.31
  HNT                             59070_at       5.37      9.69      12.08    13.67
  SDCCAG3                         43014_at       7.99      8.57      11.24    17.32
  LOC64744                        42739_at       7.3       9.64      9.57     14.51
  \-\--                           1089_i\_at     5.06      4.14      12.12    22.01
  SPP1                            2092_s\_at     14.05     12.94     3.35     4.07
  UBE2H                           58777_at       9.5       7.45      6.55     15.13
  SRPK1                           63687_at       6.06      4.36      10.61    12.82
  NCK2                            33003_at       5         9.14      8.5      7.34
  HIST1H3H                        36757_at       7.26      17.07     8.47     5.61
  PPP4R2                          48663_at       5.09      6.97      8.59     16.16
  C8orf16                         47339_at       6.54      8.15      9.53     7.39
  \-\--                           55943_at       3.41      7.47      15.31    8.01
  \-\--                           64642_s\_at    8.25      6.42      7.04     10.6
  EP400                           47518_at       5.94      9.27      4.51     9.32
  GOLT1A                          45144_at       3.9       6.17      8.37     12.32
  \-\--                           52853_g\_at    9.83      7.1       6.25     7.03
  LOC284058                       44791_at       8.25      10.17     4.55     5.86
  DAPK1                           51580_at       3.42      6.04      8.03     11.32
  NFATC2IP                        38864_at       3.26      4.83      9.58     9.19
  SEL1L                           40689_at       4.71      7.84      6.13     10.94
  TM4SF9                          47746_at       3.43      6.26      8.92     7.52
  MLLT2                           65205_at       3.43      7.13      6.57     13.01
  SC4MOL                          46802_at       22.91     7.35      5.62     6.17
  \-\--                           62671_at       6.38      7.13      5.74     11.03
  BIRC6                           46558_at       5.67      8.59      7.5      5.92
  MAP4K4                          51474_at       4.86      4.32      8.7      8.52
  MLLT2                           53300_at       4.65      3.99      9.39     8.1
  \-\--                           52851_at       8.71      5.94      6.35     6.25
  MRRF                            51635_at       4.23      4.87      7.39     8.23
  ACAS2                           62783_at       4.29      6.14      7.02     5.9
  \-\--                           60658_at       3.4       6.84      5.19     9.1
  SUMO1                           49551_at       4.05      7.2       4.77     7.75
  AR                              1578_g\_at     7.56      4.86      5.32     6.37
  GALNT7                          59101_at       8.41      4.12      5.11     6.54
  GPR75                           44203_at       5.14      8.32      3.9      6.31
  TBL1XR1                         65001_r\_at    3.53      12.3      4.06     7.19
  HSD17B12                        43292_at       4.74      8.88      3.64     6.28
  MRPS28                          43095_at       5.79      5.39      5.58     5.14
  FN1                             64719_at       27.07     6.02      4.05     4.93
  GPR158                          44214_at       7.21      3.33      4.32     6.62
  \-\--                           48069_at       6.27      9.88      3.38     4.55
  FLJ21657                        58778_at       4.34      5.6       6.17     5.18
  MLL5                            43301_at       4.76      3.61      5.87     10.34
  \-\--                           55761_at       3.78      4.88      5.65     6.93
  DLG1                            47231_at       3.4       4.77      6.22     5.7
  MYO5B                           63281_r\_at    3.29      6.17      4.29     6.84
  \-\--                           49268_at       3.55      19.86     3.61     6.75
  FUS                             43501_at       3.93      3.78      6.42     8.97
  CCDC35                          54684_at       4.9       8.14      3.55     5.43
  \-\--                           43435_at       6.85      4.83      4.82     5.49
  SMA4                            32921_at       4.68      5.53      5.74     4.26
  NCOA1                           45953_at       6.53      4.13      3.58     6.06
  S100A8                          41096_at       4.22      5.89      3.8      22.58
  PRKCBP1                         53493_at       4.65      7.37      4.5      5.35
  RNPC2                           65083_at       3.18      3.96      6.01     9.19
  CAMSAP1                         62630_at       4.45      5.8       3.36     5.36
  EEF1G                           41903_at       5.19      4.58      4.31     5.34
  EIF5                            51379_at       3.44      4.08      5.62     11.07
  MAML3                           49879_at       3.39      3.22      10.27    5.87
  C21orf106                       59651_at       3.19      4.02      5.23     6.44
  VCIP135                         42715_at       3.37      3.61      5.52     8.55
  FOXO3A                          55502_at       3.48      4.37      6.97     4.74
  C7orf20                         49143_s\_at    4.23      4.62      4.41     5.78
  GNMT                            46482_at       3.59      4.84      4.24     4.64
  DONSON                          48549_at       4.1       3.58      4.66     5.28
  \-\--                           43436_g\_at    4.98      3.75      3.58     5.09
  PKP4                            66327_at       3.31      3.88      4.56     6.2
  PCBP2                           55393_at       3.73      3.19      4.36     6.29
  CPEB4                           57169_at       3.7       3.92      4.14     4.48
  CUGBP1                          34683_at       4.26      3.76      3.13     4.78
  FALZ                            47458_at       4.21      3.65      3.82     4.09
  \-\--                           51586_at       3.51      4         4.99     3.89
  RALA                            39253_s\_at    3.92      4.3       3.29     3.85
  MLL5                            45092_at       4.36      3.21      4.48     3.39
  PABPC1                          44806_at       3.74      3.98      4.2      3.07
  EIF1AX                          34278_at       3.99      3.47      3.84     3.19
  C7orf2                          42173_at       3.15      3.27      5.07     4.04
  \-\--                           63147_at       3.25      5.4       3.12     4.04
  RAD23B                          41157_at       3.2       3.46      3.64     4.45
  \-\--                           61037_at       3.44      3.56      3.47     3.73
  NFATC1                          39143_at       3.13      3.21      9.06     3.78
  JARID1A                         50532_at       3.22      3.32      3.54     4.12
  PDLIM5                          37366_at       3.02      3.58      3.42     3.16
                                                                              
  **Downregulated Transcripts**                                               
  NEFH                            33767_at       -117.15   -147.36   -9.9     -17.18
  C10orf116                       32527_at       -35.49    -29.63    -46.85   -66.5
  KLK11                           40035_at       -23.65    -19.24    -39.73   -62.15
  FAM3B                           59657_at       -15.81    -27.92    -26.09   -25.97
  PGM5                            52140_at       -23.87    -26.5     -44.27   -17.72
  MRGPRF                          52946_at       -15.61    -18.57    -30.59   -70.95
  KRT15                           37582_at       -21.85    -20.74    -19.22   -33.68
  PTN                             34820_at       -11.62    -31.95    -10.24   -27.11
  SELM                            64449_at       -6.36     -8.4      -29.23   -39.36
  MYLK                            46276_at       -5.87     -15.22    -22.57   -20.86
  SYNPO2                          50361_at       -15.14    -15.77    -20.15   -84.14
  KRT5                            613_at         -13.21    -11.12    -22.66   -32.96
  FOS                             2094_s\_at     -10.72    -25.75    -13.72   -16.45
  PKP1                            51214_at       -11.57    -16.34    -11.83   -17.85
  \-\--                           42921_at       -9.96     -11.67    -15.61   -16.5
  RAB34                           45269_at       -14.36    -11.54    -17.49   -10.35
  \-\--                           48927_at       -10.61    -14.93    -8.77    -21.91
  ALOX15B                         37430_at       -12.47    -12.41    -14.17   -9.1
  FOS                             1915_s\_at     -7.59     -26.38    -11.03   -12.11
  TMEM16G                         62387_at       -9.63     -13.32    -12.59   -9.93
  \-\--                           64676_at       -17.3     -9.39     -6.32    -13.05
  SFRP1                           32521_at       -13.1     -5.73     -8.29    -16.73
  NDFIP2                          60510_at       -7.2      -9.23     -11.72   -15.15
  FHOD3                           50298_at       -9.96     -12.84    -5.59    -10.96
  WNT5B                           61292_s\_at    -8.72     -11.85    -5.42    -13.92
  SYNPO2                          48039_at       -11.04    -8.8      -12.64   -9.34
  BOC                             64423_s\_at    -3.63     -8.16     -11.8    -54.66
  SLC20A2                         1137_at        -9.27     -5.08     -10.51   -12.61
  COL8A2                          52652_g\_at    -7.95     -9.99     -11.56   -9.75
  \-\--                           52678_at       -9.69     -9.99     -3.76    -17.93
  FOS                             1916_s\_at     -7.58     -21.81    -6.93    -11.58
  ARGBP2                          51939_at       -7.77     -13.86    -10.4    -8.71
  CTGF                            64342_at       -4.21     -4.15     -20.44   -14.87
  EPHB6                           39930_at       -8.61     -9.66     -8.32    -19.41
  SYNPO2                          60532_at       -9.77     -5.54     -8.77    -9.03
  NR4A1                           280_g\_at      -8.68     -13.49    -5.82    -8.58
  DKFZP564O0823                   54033_at       -4.67     -3.72     -11.83   -20
  GSTO2                           45609_at       -4.73     -6.81     -9.6     -16.18
  \-\--                           49321_at       -7.91     -8.41     -9.24    -3.88
  EGR3                            40375_at       -9.89     -7.71     -8.49    -6.44
  SYNPO2                          61681_at       -7.85     -8.33     -4.56    -18.57
  PI15                            58361_at       -3.59     -4.26     -12.77   -11.74
  FOSB                            36669_at       -8.81     -6.27     -7.6     -8.39
  OGN                             43507_g\_at    -3.56     -8.26     -7.19    -25.54
  MOXD1                           36834_at       -5.4      -11.7     -10      -3.85
  LSAMP                           43930_at       -3.05     -7.62     -9.76    -7.67
  EGR2                            37863_at       -7.7      -5.52     -7.23    -15.41
  DKFZp686D0853                   49770_at       -10.18    -7.66     -7.16    -4.39
  LGP1                            52826_at       -13.75    -5.94     -3.83    -8.11
  ME3                             35216_at       -7.45     -9.26     -6.54    -5.32
  PPP1R14A                        58774_at       -6.68     -6.14     -7.31    -7.87
  FLJ22386                        50198_at       -6.8      -3.64     -6.98    -6.65
  NR4A1                           279_at         -5.31     -8.04     -5.11    -8.48
  WFDC1                           64111_at       -3.79     -11.21    -6.64    -6.66
  ZFP36                           40448_at       -6.39     -6.86     -7.25    -3.61
  CACHD1                          43554_at       -6.68     -3.34     -17.46   -6.57
  RLN1                            35070_at       -6.78     -11.78    -5.14    -6.39
  \-\--                           49975_at       -6.43     -6.16     -6.74    -10.11
  CYBRD1                          65852_at       -6.43     -4.79     -6.7     -7.23
  PER3                            53766_at       -15.43    -6.79     -5.56    -6.29
  MN1                             37283_at       -4.47     -7.36     -5.55    -7.48
  DNCI2                           35788_at       -4.2      -8.68     -3.02    -10.64
  MRVI1                           43966_at       -6.76     -5.28     -12.19   -6.09
  AZGP1                           35834_at       -6.32     -3.86     -38.18   -6.18
  MGC14839                        48949_at       -8.96     -4.19     -8.25    -3.61
  SMTN                            64499_s\_at    -5.2      -15.22    -7.18    -4.42
  HSPC157                         50179_at       -5.66     -3.18     -6.63    -8.09
  WFDC2                           33933_at       -5.3      -6.5      -5.73    -6.81
  BTG2                            36634_at       -6.99     -3.13     -9.25    -5.22
  AXIN2                           64129_at       -4.97     -6.97     -7.18    -4.2
  PDGFC                           45217_at       -4.32     -7.53     -8.81    -3.97
  MLLT10                          63345_at       -7.2      -5.85     -5.9     -3.84
  BMP7                            49273_g\_at    -4.58     -4.89     -6.82    -13.13
  MCC                             49504_r\_at    -5.9      -5.71     -5.08    -5.84
  HEXA                            39340_at       -8.15     -5.65     -4.18    -5.88
  GSTT2                           1099_s\_at     -6.47     -5.05     -6.8     -4.66
  SSPN                            65647_at       -5.4      -5.88     -3.12    -17.61
  UPK3A                           36379_at       -5.37     -4.71     -5.81    -6.91
  PDE5A                           54668_at       -4.44     -5.17     -5.87    -9.56
  PSD3                            63832_at       -3.19     -6.04     -4.98    -6.58
  ALDH7A1                         61965_at       -5.85     -5.14     -5.88    -3.13
  FMOD                            33431_at       -7.62     -4.3      -4.9     -6.04
  TSPAN2                          53693_at       -6.38     -4.49     -4.54    -6.77
  DKFZP586H2123                   40017_at       -6.52     -6.49     -4.32    -3.91
  EFS                             33883_at       -5.43     -3.58     -6.35    -5.18
  PODN                            63953_at       -4.16     -5.3      -4.84    -4.98
  DUSP1                           1005_at        -6.53     -16.66    -3.02    -3.19
  SLC22A17                        58898_s\_at    -4.93     -5.81     -4.66    -4.44
  CDH10                           47535_at       -4.87     -3.19     -8.27    -4.65
  \-\--                           64163_at       -3.66     -5.03     -4.79    -4.7
  \-\--                           42587_at       -4.68     -4.62     -4.9     -3.45
  TSPAN2                          57331_at       -4.44     -8.06     -3.42    -4.71
  SORBS1                          56409_at       -5.45     -5.7      -3.17    -3.53
  C21orf63                        50658_s\_at    -4.54     -3.36     -4.15    -5.31
  NBL1                            37005_at       -3.34     -4.27     -4.31    -6.36
  CIRBP                           39864_at       -4.38     -3.53     -4.19    -6.8
  KLF4                            48587_at       -3.77     -3.62     -4.57    -12.5
  ZCSL2                           45320_at       -3.1      -3.19     -5.88    -5.13
  C12orf10                        53911_at       -3.62     -4.44     -3.86    -6.46
  CERKL                           60314_at       -4.68     -3.03     -7.37    -3.62
  NOV                             39250_at       -3.2      -3.9      -4.38    -7.37
  EPB41L5                         60293_at       -4.33     -4.97     -3.06    -3.92
  WNT5B                           66142_s\_at    -3.94     -3.87     -4.49    -4.16
  ACYP2                           64090_s\_at    -3.36     -4.33     -3.68    -5.82
  C9orf103                        56186_at       -3.14     -4.62     -4.03    -3.73
  FBXO2                           57811_at       -3.51     -3.37     -4.16    -5.33
  CD38                            40323_at       -3.25     -3.37     -4.27    -4.27
  BCAS1                           37821_at       -4.96     -3.19     -4.26    -3.34
  TMSL8                           36491_at       -3.03     -4.11     -3.45    -7.67
  ISL1                            39990_at       -3.12     -3.78     -3.61    -3.91
  HSPB8                           56474_at       -3.45     -3.87     -3.04    -7.5
  B3GALT3                         53879_at       -3.04     -4.02     -3.77    -3.48
  CYBRD1                          50955_at       -3.7      -3.51     -3.21    -5.6
  EFEMP2                          63644_at       -3.25     -3.91     -3.28    -3.97
  TU3A                            45260_at       -3.14     -3.94     -3.22    -4.82
  LOC57228                        34176_at       -3.68     -5.3      -3.41    -3.16
  IER2                            36097_at       -4.79     -3.2      -3.11    -3.88
  DKFZP564K1964                   65860_at       -3.53     -3.11     -3.52    -4.62

A patient-specific median expression value was calculated from the multiple samples for each patient. These median values were then compared to the primary tumor expression value and those genes with 3-fold difference between metastatic and primary prostate cancer is shown.

###### 

GO and pathway annotation of genes and pathways altered in metastatic prostate cancer

  **Probe ID**               **Gene Symbol**   **Overall FC**   **FC_P1**   **FC_P2**   **FC_P3**   **FC_P4**
  -------------------------- ----------------- ---------------- ----------- ----------- ----------- -----------
  ***Bone remodeling***                                                                             
  34342_s\_at                SPP1              24.7             24.16       26.78       4.75        5.39
  2092_s\_at                 SPP1              11.8             14.05       12.94       3.35        4.07
  47958_r\_at                ANKH              -2               -2.23       -2.31       -2.03       -3.66
  65035_at                   TF1P11            -2.31            -2.28       -2.63       -2.97       -3.77
  44596_at                   TWIST2            -2.45            -2.7        -2.12       -2.94       -2.35
  40333_at                   BMP4              -2.5             -2.86       -2.89       -3          -5.23
  49273_g\_at                BMP7              -2.81            -4.58       -4.89       -6.82       -13.13
  ***Cell Adhesion***                                                                               
  34342_s\_at                SPP1              24.7             24.16       26.78       4.75        5.39
  2092_s\_at                 SPP1              11.8             14.05       12.94       3.35        4.07
  64719_at                   FN1               7.5              27.07       6.02        4.05        4.93
  59070_at                   HNT               5                5.37        9.69        12.08       13.67
  62628_at                   PCDHGC3           3.4              2.24        5.44        2.97        2.42
  44892_at                   MLLT4             3.3              2.63        2.07        6.21        7.48
  47064_at                   HNT               3.27             2.98        4.37        8.07        8.4
  66327_at                   PKP4              2.79             3.31        3.88        4.56        6.2
  35246_at                   TYRO3             2.4              -5.43       -3.58       -6.35       -5.18
  659_g\_at                  THBS2             1.9              2.39        2.37        2.26        2.7
  59623_at                   PCDH18            -2.22            -2.09       -2.89       -2.17       -2.39
  53497_at                   ITGB8             -2.38            -2.88       -2.69       -3.51       -13.81
  60876_at                   COL8A2            -2.38            -2.26       -3.26       -3.61       -2.25
  47007_s\_at                NINJ2             -2.63            -2.55       -3.4        -3.3        -5.93
  103_at                     THBS4             -2.7             -2.02       -3.37       -2.16       -3.26
  46520_at                   ROBO2             -2.86            -2.58       -4.96       -4.14       -4.46
  45939_at                   CNTN3             -3.33            -3.38       -2.14       -7.41       -11.94
  47535_at                   CDH10             -3.7             -4.87       -3.19       -8.27       -4.65
  56192_at                   PCDH7             -3.7             -2.5        -5.33       -5.74       -3
  52999_at                   BOC               -4.17            -2.42       -8.8        -12.25      -6.16
  43930_at                   LSAMP             -4.35            -3.05       -7.62       -9.76       -7.67
  33883_at                   EFS               -4.76            -5.43       -3.58       -6.35       -5.18
  64342_at                   CTGF              -5.26            -4.21       -4.15       -20.44      -14.87
  64423_s\_at                BOC               -6.67            -3.63       -8.16       -11.8       -54.66
  52652_g\_at                COL8A2            -10              -7.95       -9.99       -11.56      -9.75
  51214_at                   PKP1              -14.29           -11.57      -16.34      -11.83      -17.85
  52140_at                   PGM5              -25              -23.87      -26.5       -44.27      -17.72
  ***Cell_cycle***                                                                                  
  47231_at                   DLG1              3.57             3.4         4.77        6.22        5.7
  45574_g\_at                TPX2              3.49             11.09       2.57        3.24        8.6
  54219_at                   7-Sep             3.23             3.3         2.79        2.17        3.27
  53998_at                   CLASP2            3.09             2.67        2.84        4.18        4.13
  37933_at                   RBBP6             3.08             2.27        5.42        7.52        8.79
  53568_at                   7-Sep             2.97             3.94        2.4         3.53        2.49
  51815_at                   TERF1             2.54             2.11        4.78        5.1         3.51
  1797_at                    CDKN2D            2.41             3.65        2.76        2.46        2.47
  50084_at                   DNCH1             2.29             2.42        2.15        2.11        2.29
  66955_at                   EML4              2.13             2.22        3.3         6.8         5.09
  1833_at                    CDK2              2.12             3.14        2.56        2.05        2.45
  52744_at                   HRPT2             2.07             2.73        2.62        3.4         3.36
  60568_at                   BCL2              2.07             2.18        3.27        3.35        3.75
  41632_at                   E2F3              2.05             2.34        2.04        2.2         2.15
  59821_at                   BCL2              1.87             2.89        3.13        3.58        3.86
  36101_s\_at                VEGF              1.53             2.5         2.38        2.53        3.06
  63158_at                   GRLF1             1.27             3.55        2.63        2.3         3.45
  65908_at                   CHES1             -2.1             -3.3        -2.11       -2.34       -5.51
  46664_at                   PYCARD            -2.14            -2.36       -2.06       -2.94       -2.08
  48980_at                   ZAK               -2.25            -2.02       -4.8        -2.06       -2.07
  36838_at                   KLK10             -2.38            -3.38       -2.94       -2.07       -6.13
  50199_s\_at                RGC32             -2.73            -2.49       -3.64       -5.45       -4.17
  39780_at                   PPP3CB            -2.74            -3.82       -2.36       -3.06       -2.85
  33864_at                   ZMYND11           -2.78            -4.77       -2.85       -3.79       -3.79
  49504_r\_at                MCC               -3.45            -5.9        -5.71       -5.08       -5.84
  37005_at                   NBL1              -3.83            -3.34       -4.27       -4.31       -6.36
  234_s\_at                  PTN               -3.86            -2.92       -5.02       -2.15       -3.33
  37283_at                   MN1               -4.63            -4.47       -7.36       -5.55       -7.48
  45217_at                   PDGFC             -4.82            -4.32       -7.53       -8.81       -3.97
  1005_at                    DUSP1             -6.16            -6.53       -16.66      -3.02       -3.19
  36669_at                   FOSB              -7.85            -8.81       -6.27       -7.6        -8.39
  34820_at                   PTN               -12.55           -11.62      -31.95      -10.24      -27.11
  37430_at                   ALOX15B           -21              -12.47      -12.41      -14.17      -9.1
  ***Transcription***                                                                               
  1577_at                    AR                10               14.35       12.97       12.24       14.78
  65001_r\_at                TBL1XR1           7                3.53        12.3        4.06        7.19
  1578_g\_at                 AR                6.18             7.56        4.86        5.32        6.37
  42733_i\_at                FOXP1             5.6              2.61        5.92        14.54       14.09
  52769_at                   POLR2A            5.1              2.93        4.04        12.61       11.14
  54342_at                   ZNF605            4.55             2.75        6.89        4.85        4.04
  65083_at                   RNPC2             4.1              3.18        3.96        6.01        9.19
  42734_r\_at                FOXP1             3.5              2.01        4.49        7.53        8.6
  48423_at                   ZNF621            3.4              2.11        8.51        3.74        7.33
  51543_at                   ZNF395            3.32             2.99        5.52        6.73        6.51
  44546_at                   ZNF148            3                3.32        2.59        4.72        4.18
  49633_at                   HES6              3                5.76        2.26        2.34        6.72
  51842_at                   CBX4              3                3.32        2.61        5.21        3.08
  54981_r\_at                SFPQ              3                2.27        4.87        4.9         5.33
  60076_at                   SOX4              3                3.32        3.77        2.09        2.72
  43580_at                   MORF4L2           2.93             2.42        3.49        3.38        6.52
  34715_at                   FOXM1             2.84             6.82        2.17        2.9         2.99
  40674_s\_at                HOXC6             2.81             3.09        2.48        6.67        4.56
  56981_at                   ZKSCAN1           2.77             2.65        2.4         2.6         4.04
  55293_at                   ADNP              2.73             2.44        3.6         3.98        3.9
  43545_at                   ZNF281            2.7              2.17        3.21        3.05        4.19
  32653_at                   BRD8              2.56             2.11        3.73        3.22        4.45
  53846_at                   FLJ21616          2.55             3.1         2.96        5.41        5.92
  45953_at                   NCOA1             2.42             6.53        4.13        3.58        6.06
  46006_at                   ERCC8             2.35             2.35        2.7         3.36        5.84
  50911_at                   RLF               2.35             2.18        2.38        4.07        4.92
  58641_at                   MAML3             2.33             2.86        2.31        5.61        5.44
  42571_at                   MORF4L2           2.32             2.21        3.7         3.99        3.48
  43120_at                   MLL3              2.32             2.55        2.48        2.14        2.74
  31437_r\_at                ESR2              2.3              2.06        3.06        3.13        4.09
  50532_at                   JARID1A           2.3              3.22        3.32        3.54        4.12
  44939_at                   MLL3              2.22             2.55        2.48        2.14        2.74
  55502_at                   FOXO3A            2.21             2.44        3.6         3.98        3.9
  52328_at                   SP3               2.2              2.13        2.62        3.38        3.11
  54220_r\_at                NLK               2.16             2.39        4.23        3.94        4.41
  41632_at                   E2F3              2.04             2.34        2.04        2.2         2.15
  66313_at                   HIPK1             2                2.09        2.85        2.95        3.98
  42193_r\_at                \-\--             1.9              2.16        2.04        2.66        3.29
  39540_at                   ZBTB7A            1.89             2.42        3.27        3.03        2.61
  63158_at                   GRLF1             1.79             3.55        2.63        2.3         3.45
  65908_at                   CHES1             -2.13            -3.3        -2.11       -2.34       -5.51
  36770_at                   STAT2             -2.17            -2.3        -3.47       -2.82       -3.75
  64963_at                   EYA4              -2.17            -3.06       -3.31       -2.55       -5.01
  65945_at                   PNRC2             -2.17            -2.08       -2.26       -2.61       -2.24
  1454_at                    SMAD3             -2.27            -2.17       -2.51       -2.02       -2.07
  54658_at                   PSPC1             -2.33            -3.18       -2.22       -3.63       -13.16
  44596_at                   TWIST2            -2.5             -2.7        -2.12       -2.94       -2.35
  46704_at                   KLF3              -2.63            -2.38       -2.29       -2.19       -3.33
  51253_at                   ZBTB4             -2.63            -2.92       -3.18       -2.63       -3.93
  287_at                     ATF3              -2.78            -2.11       -2.33       -2.63       -3.3
  33864_at                   ZMYND11           -2.78            -4.77       -2.85       -3.79       -3.79
  63526_f\_at                KLF6              -2.78            -3.21       -2.48       -2.71       -3.33
  64932_at                   VPS36             -2.86            -4.56       -2.88       -2.48       -2.27
  45680_at                   ZNF537            -2.94            -2.77       -3.37       -2.78       -3.74
  43431_at                   SOX2              -3.03            -2.09       -3.8        -7.43       -7.34
  47620_at                   XAB2              -3.33            -2.7        -8.25       -7.6        -8.49
  465_at                     HTATIP            -3.45            -2.52       -2.37       -4.49       -2.47
  37863_at                   EGR2              -4.55            -7.7        -5.52       -7.23       -15.41
  48587_at                   KLF4              -4.76            -3.77       -3.62       -4.57       -12.5
  36634_at                   BTG2              -5.26            -6.99       -3.13       -9.25       -5.22
  279_at                     NR4A1             -6.25            -5.31       -8.04       -5.11       -8.48
  280_g\_at                  NR4A1             -7.14            -8.68       -13.49      -5.82       -8.58
  40375_at                   EGR3              -8.33            -9.89       -7.71       -8.49       -6.44
  53766_at                   PER3              -9.09            -15.43      -6.79       -5.56       -6.29
  ***MAP Kinase Pathway***                                                                          
  1562_g\_at                 DUSP8             5.8              2.42        5.01        16.6        5.86
  1104_s\_at                 HSPA1A/HSPA1B     4.1              7.81        2.77        2.81        5.02
  51474_at                   MAP4K4            3.57             4.86        4.32        8.7         8.52
  60658_at                   \-\--             3.5              -3          -2.96       -3.6        -3.73
  50375_at                   SOS1              3                2.97        4.08        4.57        3.79
  33855_at                   GRB2              2.55             2.29        2.61        3.85        2.1
  42838_f\_at                MAP3K8            2.3              2.25        3.4         2.78        2.08
  54220_r\_at                NLK               2.16             2.39        4.23        3.94        4.41
  790_at                     NGFB              1.86             2.08        2.35        3.37        2.9
  48980_at                   ZAK               -2.27            -2.02       -4.8        -2.06       -2.07
  43053_g\_at                PAK1              -2.7             -6.31       -2.46       -2.83       -2.11
  39780_at                   PPP3CB            -2.78            -3.82       -2.36       -3.06       -2.85
  468_at                     FGF13             -2.78            -4.35       -4.35       -2.11       -2.56
  65904_at                   \-\--             -2.94            -2.05       -3.48       -4.18       -3.43
  1292_at                    DUSP2             -3.13            -3.72       -3.66       -3.17       -2.19
  57299_s\_at                RRAS              -3.23            -3          -2.96       -3.6        -3.73
  1970_s\_at                 FGFR2             -5.56            -2.55       -13.13      -8.88       -4.92
  1005_at                    DUSP1             -6.25            -6.53       -16.66      -3.02       -3.19
  279_at                     NR4A1             -6.25            -5.31       -8.04       -5.11       -8.48
  280_g\_at                  NR4A1             -7.14            -8.68       -13.49      -5.82       -8.58
  1916_s\_at                 FOS               -7.69            -7.58       -21.81      -6.93       -11.58
  1915_s\_at                 FOS               -9.09            -7.59       -26.38      -11.03      -12.11
  2094_s\_at                 FOS               -16.67           -10.72      -25.75      -13.72      -16.45

Genes whose median value shows at least 2 fold change in every metastatic patient were annotated by NIH\'s DAVID tool. Genes belonging to selected GO categories with a significant number of differentially expressed genes are shown. *Overall_FC*, the fold change in the mean expression value of all metastatic samples compared to the primary samples;*FC_P1, FC_P2, FC_P3, FC_P4*; a patient-specific median expression value was calculated using all the samples from each patient. This was compared to the median value for the primary tumors. Patient P4 had only sample and this was considered the median.
